Table 1.
Role of metformin in multiple sclerosis (MS)
Study type | Findings | References |
---|---|---|
An experimental study | Metformin 100 mg/kg/day attenuates experimental autoimmune encephalomyelitis in mice by down-regulating the expression of pro-inflammatory cytokines, inducible nitric oxide synthase (iNOS)), cell adhesion molecules, and chemokine | Nath et al. [125] |
An experimental study | Metformin 100 mg/kg/day in mice reduced Th17 and increased Treg cell percentages along with the levels of associated cytokines in experimental autoimmune encephalomyelitis | Sun et al. [126] |
A case control study | Metformin 850–1500 mg/day has anti-inflammatory effects in patients with MS by increasig in the number and regulatory functions of regulatory T cells compared with controls | Negrotto et al. [127] |
A placebo-controlled clinical trial | Metformin 850 mg/twice daily improves fibrinolysis in obese patients | Charles et al. [144] |
An experimental study | Metformin therapy 100 mg/kg/day significantly alleviated reactive microgliosis and astrogliosis in mice with experimental autoimmune encephalomyelitis | Abdi et al. [145] |